Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study

Author:

Jaeger Veronika K1ORCID,Tikly Mohammed2,Xu Dong3,Siegert Elise4,Hachulla Eric5,Airò Paolo6,Valentini Gabriele7,Matucci Cerinic Marco8,Distler Oliver9,Cozzi Franco10,Carreira Patricia11,Allanore Yannick12,Müller-Ladner Ulf13,Ananieva Lidia P14,Balbir-Gurman Alexandra15,Distler Jörg H W16,Czirják Laszlo17,Li Mengtao3,Henes Jörg18,Jimenez Sergio A19ORCID,Smith Vanessa20ORCID,Damjanov Nemanja21,Denton Christopher P22ORCID,DelGaldo Francesco23,Saketkoo Lesley Ann24,Walker Ulrich A1,

Affiliation:

1. Department of Rheumatology, University Hospital Basel, Basel, Switzerland

2. Division of Rheumatology, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa

3. Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China

4. Department of Rheumatology and Immunology, University Hospital Charité, Berlin, Germany

5. Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord et Nord-Ouest (CERAINO), LIRIC, INSERM, Univ. Lille, CHU Lille, Lille, France

6. UO Reumatologia ed Immunologia Clinica, Spedali Civili, Brescia, Italy

7. Rheumatology Department, Second University of Naples, Naples, Italy

8. Department of Experimental and Clinical Rheumatology, Division of Rheumatology AOUC, University of Florence, Florence, Italy

9. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

10. Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy

11. Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Spain

12. Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Paris, France

13. Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Germany, Bad Nauheim

14. VA Nasonova Institute of Rheumatology, Moscow, Russian Federation

15. B. Shine Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion – Institute of Technology, Haifa, Israel

16. Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

17. Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary

18. Department of Internal Medicine II, Eberhard-Karls-University Tübingen, Tübingen, Germany

19. Scleroderma Centre, Thomas Jefferson University, Philadelphia, PA, USA

20. Faculty of Internal Medicine, Ghent University, Ghent, Belgium

21. Institute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia

22. Department of Rheumatology, University College London, Royal Free Hospital, London, UK

23. Leeds Musculoskeletal Biomedical Research Unit (LMBRU), University of Leeds, Leeds, UK

24. Tulane University Lung Centre, University Medical Centre Scleroderma and Sarcoidosis Patient Care and Research Centre, New Orleans, LA, USA

Abstract

Abstract Objectives Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. Methods SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. Results The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. Conclusion Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3